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Conformational plasticity of ligand-bound and
ternary GPCR complexes studied by 19F NMR
of the β1-adrenergic receptor
J. Niclas Frei1, Richard W. Broadhurst 1, Mark J. Bostock 1,3, Andras Solt1, Andrew J.Y. Jones1, Florian Gabriel1,
Aditi Tandale1, Binesh Shrestha2 & Daniel Nietlispach 1*
G-protein-coupled receptors (GPCRs) are allosteric signaling proteins that transmit an
extracellular stimulus across the cell membrane. Using 19F NMR and site-speciﬁc labelling,
we investigate the response of the cytoplasmic region of transmembrane helices 6 and 7 of
the β1-adrenergic receptor to agonist stimulation and coupling to a Gs-protein-mimetic
nanobody. Agonist binding shows the receptor in equilibrium between two inactive states and
a pre-active form, increasingly populated with higher ligand efﬁcacy. Nanobody coupling
leads to a fully active ternary receptor complex present in amounts correlating directly with
agonist efﬁcacy, consistent with partial agonism. While for different agonists the helix 6
environment in the active-state ternary complexes resides in a well-deﬁned conformation,
showing little conformational mobility, the environment of the highly conserved NPxxY motif
on helix 7 remains dynamic adopting diverse, agonist-speciﬁc conformations, implying a
further role of this region in receptor function. An inactive nanobody-coupled ternary
receptor form is also observed.
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G-protein-coupled receptors (GPCRs) are a family ofplasma membrane-embedded, seven transmembranesensors that respond to a wide range of extracellular
ligands1. GPCRs act as signal transducers stimulating a response
on the cytoplasmic side of the membrane via a range of intra-
cellular binding partners (IBPs), including G proteins and β-
arrestins2,3. With just over 800 GPCRs in humans they are the
largest class of membrane proteins4. Signal transduction occurs
following ligand binding, which leads to an allosteric conforma-
tional signal response, whereupon changes induced by the bind-
ing event at the extracellular side of the receptor drive
conformational rearrangements at the cytoplasmic face, leading
to coupling with IBPs5. Due to their central role in signal
transduction GPCRs are involved in a wide range of physiological
processes and consequently, are key proteins in many disease
pathways6. Class A or rhodopsin-like GPCRs are the targets for
around 1/3 of currently available drugs6,7.
Receptor regulation of the signalling process occurs at multiple
levels, involving binding of orthosteric agonists as well as allos-
teric modulators such as lipids8. Our understanding of GPCR
signalling has been greatly enhanced by crystal structures of
receptors in the inactive, ligand-bound and fully active (coupled
to IBPs) states9–11. In addition to this static picture, NMR spec-
troscopy has demonstrated that these receptors are highly
dynamic proteins, which populate multiple states that are in
equilibrium with each other12. NMR has determined exchange
kinetics and populations for some of these interconverting
states13,14. Investigations of several class A receptors have
revealed that their energy landscapes are unique with the differ-
ences relating to their individual signalling properties15–21.
We investigate the conformational energy landscape of the
β1-adrenergic receptor (β1AR). β-adrenergic receptors are central
receptors in the sympathetic nervous system, which bind cate-
cholamine ligands such as adrenaline or noradrenaline22,23.
The β1AR is the predominant subtype in the heart, which is
targeted by drugs such as β-blockers in the context of cardiac
dysfunction22.
Agonist-inﬂuenced equilibria between different receptor
states of β1AR were recently described by 15N and 13C directed
studies16,17. In our recent 13C methionine NMR study, we
presented evidence for equilibria between an inactive and pre-
active state as well as for the existence of two interconverting
ternary complexes17. Both equilibria were seen to be inﬂuenced
by ligand efﬁcacy, as evidenced by residues on transmembrane
helices 5 and 6 (TM5 and TM6) located adjacent to the receptor
binding pocket (M2235.54, M2966.41) (superscripts refer to
Ballesteros-Weinstein numbering24). These results corrobo-
rated and extended the identiﬁcation of ligand-efﬁcacy depen-
dent equilibria and allosteric signalling in β1AR using 15N
valine-probes16.
NMR studies to date have provided detailed descriptions of
β1AR signalling using a range of probes. However, due to a lack of
suitable reporters, only a limited description of the response of the
important cytoplasmic region of the receptor to activation, crucial
for IBP interaction, is available. Crystal structures of receptor
ternary complexes of β1AR show the large amplitude outward
movement of TM6, typical of activated GPCRs11. Previously, both
15N-labelled V2806.25 16 and 13C-labelled M2836.28 17 located at
the cytoplasmic side of TM6 were observed to be insensitive
towards ligand-based receptor activation, likely due to these
probes facing the detergent micelle. Furthermore, there is little
information about the role of the highly conserved NPxxY
structural motif on TM7 for β1AR during receptor activation25.
After a rotamer change following agonist activation, the side chain
of Y7.53 in the ternary complex forms a water-mediated hydrogen
bond with Y5.58 which stabilises the fully active state of the
receptor26. The TM7-helix 8 region has also been suggested to
play a substantial role in the coupling speciﬁcity of both arrestins
and G proteins18,27.
We utilise the natural occurrence of C3447.54 positioned after
the NPxxY7.53 motif at the end of TM7 in combination with
ﬂuorine-tagging to explore the cytoplasmic side of TM7 upon
ligand binding and nanobody coupling (Fig. 1, Supplementary
Fig. 1) using 19F NMR. Furthermore, we introduce Cys2826.27 at
the equivalent position to C2656.27 in the β2AR for a more
detailed mechanistic investigation of the intracellular region of
TM6 (Fig. 1, Supplementary Fig. 1). 19F NMR studies have been
widely used to investigate the conformational equilibria of GPCRs
including the β2AR and A2AAR receptors18–21,28–32. Using these
two reporter cysteines combined with an NMR active 19F-TET
tag (Supplementary Fig. 2), we investigate the dynamic response
of previously unexplored regions of the cytoplasmic face of the
turkey β1AR to ligand binding and ternary complex formation,
using a G protein-mimetic nanobody. Allosteric signal trans-
duction from the orthosteric ligand-binding pocket on the
extracellular side of β1AR to the cytoplasmic IBP interface, reveals
a shifting equilibrium between inactive and active states, corre-
lating with ligand efﬁcacy. β1AR coupling to nanobody results in
the formation of active as well as inactive ternary complexes, with
the amount of active ternary complex correlating with the efﬁcacy
of the bound ligand. Hence, our study provides direct structural
evidence for the formation of the active-state ternary complex in
proportions reﬂecting the ligand efﬁcacy, which in turn deﬁnes
the subsequent level of downstream signalling β1AR. Interest-
ingly, the conformational response in the two cytoplasmic regions
on TM6 and TM7 of the ternary receptor complex is different.
The response of TM6 indicates the formation of a single, well-
ordered active-state ternary conformation in this region of the
receptor, determined by the coupling partner, which is indepen-
dent of the agonist type and shows little additional conforma-
tional dynamics. In contrast, TM7 in the vicinity of the NPxxY
motif shows ligand-dependent conformational variability in the
complex with extensive μs-to-ms dynamics and conformational
features at the cytoplasm that are determined by the bound
orthosteric ligand. Beyond the stabilisation of the active state, our
observations suggest an involvement of the NPxxY microdomain
during receptor activation in a manner that is predominantly
related to the properties of the orthosteric ligand bound. This
suggests a mechanistic role of this receptor region that might be
independent of the coupled G protein, enabling the binding of
further IBPs and resulting in a change in signalling bias or
strength.
Results
Ligand binding conformational equilibria of TM6 and TM7.
To obtain information on the response of the cytoplasmic region
of turkey β1AR to ligand binding, individual samples of β1AR-m-
TM6-CysΔ2 (Fig. 2a, Supplementary Note 1, Supplementary
Figs. 4, 6a) and β1AR-m-CysΔ2 (Fig. 2b, Supplementary Note 1,
Supplementary Figs. 4, 5, 6b) solubilized in LMNG detergent
micelles were investigated by 1D 19F NMR upon addition of
saturating amounts of agonists, including in order of increasing
efﬁcacy for TM6 atenolol, carvedilol, alprenolol, xamoterol, iso-
prenaline and for TM7 atenolol, carvedilol, alprenolol, cyano-
pindolol, bucindolol, xamoterol, isoprenaline and the natural
ligand adrenaline (Supplementary Table 1). Bucindolol and car-
vedilol are known to be biased agonists for β1AR33–36. In the
ligand-free apo state, A282CTET, 6.27 on TM6 appeared as a single
sharp peak, P1 (Fig. 2a). Only minor changes in chemical shift
and linewidth were observed upon binding to the different ago-
nists (Supplementary Fig. 6a, Supplementary Table 2). Although
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there was no systematic correlation with ligand efﬁcacy, line-
widths were slightly increased when bound to the higher efﬁcacy
agonists (Supplementary Fig. 7), suggesting some exchange
broadening when bound to these latter ligands. For each of the
current 19F spectra the signal P1 could be deconvoluted with a
single Lorentzian line (Supplementary Fig. 8, Supplementary
Table 2). Comparing the R2 values of apo β1AR and isoprenaline
bound receptor substantiated the presence of a small exchange
contribution to the linewidth of P1 (Supplementary Table 2). The
failure to detect a more substantial response at the cytoplasmic
side of TM6 parallels recent observations made in our 13C
methionine NMR study using the immediately neighbouring
residue on TM6, M2836.28, as a probe17. Despite demonstrating
via other residues e.g. M2966.41 located on TM6 closer to the
ligand-binding pocket that β1AR-m responds in an efﬁcacy
dependent manner to stimulation by agonists, the detergent
exposed M2836.28 showed only small changes17.
To examine whether P1 was undergoing sub-second con-
formational exchange with other very low populated states, we
conducted a series of saturation transfer experiments with the apo
receptor and the isoprenaline bound receptor, respectively. We
scanned a region from −1100 to +1100 (±2 ppm) relative to the
main peak P1 in steps of 100 Hz but found no evidence of
exchange.
Comparable 19F NMR experiments were conducted with
β1AR-m-CysΔ2 and agonists using TETC3447.54 on TM7 to
probe the conformational response of the region immediately
adjacent to the NPxxY7.53 motif (Fig. 1). A single signal P2 (I1
state) was observed for the receptor apo form that shifted
gradually towards higher ﬁeld as receptor samples were bound to
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Fig. 1 Structure overlay illustrating conformational changes in β1AR upon activation. a Side-on view of β1AR bound to cyanopindolol, representative of
the inactive state (magenta, PDB code 2YCY), and the nanobody Nb80 coupled receptor bound to isoprenaline, showing β1AR in the fully active state (blue,
PDB code 6H7J). TM6, TM7 and helix 8 are shown in the colour of their respective state, with the Gs mimetic nanobody omitted for purposes of clarity.
The 19F tagged cysteines A282CTET, 6.27 and TETC3447.54 are shown with their side chains represented as sticks and the Sγ atom as coloured spheres. The
structure overlay highlights the outward movement of TM6 and the rotation of TM7 upon formation of the ternary complex. b Enlarged view showing the
NPxxY7.53 motif on TM7 containing the highly conserved Y3437.53 that upon formation of the ternary complex rotates behind TM6 and makes a water-
mediated hydrogen bond with Y2275.58 on TM5 that stabilises the active state. Both Y3437.53 and TETC3447.54 rotate inwards upon formation of the
ternary complex. c Cytoplasmic view of the region shown in (b), which illustrates the clockwise rotation of Y3437.53 and TETC3447.54 on TM7.
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ligands of increasing efﬁcacy (Fig. 2b, Supplementary Fig. 6b).
Although the chemical shift changes were small (<0.06 ppm), they
were accompanied by a considerable broadening of the signal
linewidth on binding to agonists of higher Gs efﬁcacy (Fig. 2c, d,
Supplementary Fig. 6b). This was particularly noticeable for
xamoterol, isoprenaline and adrenaline, suggesting growing
contributions to the receptor linewidth due to μs-to-ms timescale
exchange. Signal positions and linewidths both correlated with
the efﬁcacy of the ligand bound (Fig. 2c, d). All signals for P2
were deconvoluted with a single Lorentzian line with no evidence
of multiple overlapping peaks (Supplementary Figs. 8, 20,
Supplementary Table 2). Hence, the line broadening with the
receptor bound to high efﬁcacy agonists was further investigated
through 19F NMR CPMG experiments that were performed at
564 and 658MHz (19F) and showed the effective removal of
exchange broadening for TETC3447.54 as the pulsing rate νCPMG
was increased from 100 to 5000 Hz (Fig. 2e). No measurable
exchange contribution was detected for the apo receptor. By
ﬁtting the CPMG data for xamoterol and isoprenaline and
reconstructing the corresponding spectral shifts of P2 relative to
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the apo receptor position, exchange parameters were determined
for xamoterol (kex= 1,913 ± 299 s−1, pI2= 0.11 ± 0.01) and iso-
prenaline (kex= 2,878 ± 317 s−1, pI2= 0.29 ± 0.04) bound recep-
tor (Fig. 2e, Supplementary Fig. 6b, Supplementary Table 2).
Applying the saturation transfer technique to a region
surrounding the P2 peak (Fig. 3) a substantial drop in the P2
intensity revealed the presence of a previously invisible receptor
signal, P3 (A state), at a position 300 Hz upﬁeld from the
corresponding signal P2 (Fig. 3c). With the saturating ﬁeld
positioned on P3, a saturation time course was recorded for the
apo receptor and for the receptor bound to isoprenaline (Fig. 3d).
A reference series with the position of the saturating ﬁeld held at
a distance 300 Hz downﬁeld from P2 was also acquired. Both time
intensity series for P2 were ﬁt simultaneously and analysis gave
an exchange rate kex = 6.9 ± 1.8 s−1 and a population pP3=
0.20 ± 0.04 for the isoprenaline bound receptor. For the apo form
of the receptor the population of P3 dropped further to pP3=
0.15 ± 0.04, with kex= 3.6 ± 2.2 s−1. All ﬁts of the saturation data
required the transverse relaxation rate R2 of the lower populated
species P3 to be set to a substantially larger value (R2P3= 600 Hz)
than for the main peak P2 (R2P2= 80 Hz for apo, R2P2= 140
Hz for isoprenaline bound). The broad linewidth explains why it
had not been possible to observe the peak P3 directly by 1D 19F
NMR (Fig. 3a, b).
Formation of multiple ternary complexes with nanobody
Nb6B9. To observe the 19F NMR response of TM6 upon coupling
to an IBP the apo receptor β1AR-m-TM6-CysΔ2 was supple-
mented with a two-fold excess of Gαs mimetic nanobody Nb6B9.
This revealed the appearance of a new, lower intensity signal P4
for A282CTET, 6.27 at −65.4 ppm, shifted downﬁeld by 0.9 ppm
from the P1 signal of the ligand-free apo receptor, in addition to
P1 (Fig. 4a). With the same two-fold excess of nanobody, the
experiment was repeated with samples of receptor bound to one
of the agonists carvedilol, cyanopindolol, xamoterol or iso-
prenaline, respectively (Fig. 4a). Each ternary complex showed a
P4 signal of very similar chemical shift, with linewidths that were
narrower than those of the corresponding P1 signal (Supple-
mentary Table 2). All of the P4 signals could be deconvoluted as a
single Lorentzian line (Supplementary Fig. 8, Supplementary
Table 2). A steady rise of the P4 signal intensity with increasing
efﬁcacy of the receptor-bound agonist revealed the formation of
more ternary complex (AG+) with a concomitant decrease of the
P1 signal intensity (Fig. 4a). The integrated relative signal area of
P4 for the different nanobody complexes correlated well with the
efﬁcacy of the agonist bound (R2= 0.96) (Fig. 4c). Subsequently
the same experiments were also repeated for carvedilol, xamoterol
and isoprenaline with 5-fold and 10-fold excess of nanobody and
revealed that for these ligands, the ternary complex formation
followed saturation behaviour, with the ﬁnal amount of P4
determined by the agonist efﬁcacy (Supplementary Fig. 9a).
The same series of measurements using a two-fold excess of
nanobody was repeated with β1AR-m-CysΔ2 to assess the
response of TM7 TETC3447.54 upon Nb6B9 binding (Fig. 4b,
Supplementary Fig. 21). For each of the agonists used the
experiments showed a new peak P5 for TETC3447.54 that was
shifted downﬁeld from P2 by approximately 0.7 ppm and was
attributed to the active ternary receptor complex (AG+).
However, in contrast to TM6, the TM7 region of the receptor
in its apo form as well as when bound to the different agonists
responded differently to nanobody binding, and resulted in
P5 signals that varied in their position over a range of ~0.3 ppm,
suggesting conformational differences on TM7 amongst the
ternary complexes (AG+) formed (Fig. 4b, Supplementary Fig. 9c,
d). In contrast to the reduction in linewidth between P1 and P4
for A282CTET, 6.27 (Fig. 4a, Supplementary Table 2), the signals of
P5 for TETC3447.54 were substantially broadened when compared
to their corresponding P2 signal (Fig. 4b, Supplementary Table 2).
Again, the relative signal area of the active ternary peaks
P5 showed excellent correlation with the efﬁcacy of the ligands
bound to the receptor (Fig. 4d), and a similar saturation
behaviour as observed for TM6 upon addition of 5- and 10-
fold excess of nanobody, respectively (Supplementary Fig. 9a).
Careful inspection of the signal area in the vicinity of the
ligand-bound uncoupled receptor peak P2 near −65.5 ppm
revealed the presence of an additional, broader peak P6 (AG−)
superimposed at a position very similar to P2 (Supplementary
Fig. 9b). At the larger excess of nanobody the relative size of this
broad P6 signal rapidly overtook the signal intensity of the
sharper P2 signal of the uncoupled receptor. The presence of P6
was easily inferred from the increasingly broader appearance of
the signal at the 5- and 10-fold excess of nanobody, indicating
that the signal envelope at −65.5 ppm was increasingly
dominated by the presence of more P6 as the remaining free
receptor (P2) eventually bound to nanobody (Supplementary
Fig. 9b). Except for isoprenaline the region around P2 required
two Lorentzian signals for a satisfactory deconvolution resulting
in a sharper component for P2 and a broader component for P6.
The broader component became increasingly more intense in the
presence of larger excess in nanobody (Supplementary Fig. 8,
Supplementary Table 2). With the shift positions of P2 and P6
being very similar and due to a lower signal-to-noise ratio the
deconvolution of the isoprenaline receptor region around P2
returned a single Lorentzian with a linewidth between the one of
the sharper P2 and the broader P6 (Supplementary Table 2).
Accordingly, all studies conducted in the presence of nanobody
Fig. 2 19F NMR spectroscopy of β1AR TM6 and TM7. The individual helices were studied by monitoring A282CTET (a) and TETC344 (b), respectively,
highlighting the response of the receptor to agonist binding and the formation of the ternary complex coupled to Nb6B9. All spectra were obtained at 308
K, 564MHz (19F) with receptor concentrations of 20 to 30 µM and saturating ligand concentrations (1 mM). a 19F NMR spectra are shown for A282CTET
for apo β1AR (light green), bound to full agonist isoprenaline (red) and with isoprenaline in ternary complex coupled to Nb6B9 (black). The peak
corresponding to TM6 A282CTET in the apo and isoprenaline bound β1AR (P1) appears at a chemical shift of −66.3 ppm. Addition of a two-fold molar
excess of Nb6B9 causes a downﬁeld shift of 0.8 ppm to −65.5 ppm (P4). The line marked with Δ indicates the appearance of free TET due to the slow
cleavage of the S-S bond at 308 K. b 19F NMR spectra for TM7 C344TET show a peak at −65.4 ppm (P2) for the apo β1AR (light green). Isoprenaline
binding (red) causes an upﬁeld shift by 0.06 ppm and a doubling of the linewidth. Coupling to Nb6B9 (black) shifts the signal of the ternary complex (P5)
downﬁeld to −64.8 ppm, together with a dramatic increase in the linewidth, compared to both isoprenaline bound and apo β1AR. For TETC344 on TM7 the
chemical shifts (c) and the linewidths (d) of P2 correlate with the Gs efﬁcacy of the agonists tested. Chemical shifts and linewidths are shown relative to
the apo receptor (δ=−54.42 ppm, Δv1/2= 46 Hz). Linear ﬁts of the correlations are indicated by a line and R2 values are given (ATE atenolol, CVD
carvedilol, ALP alprenolol, CYA cyanopindolol, XAM xamoterol, ISO isoprenaline, ADR adrenaline). e Fast timescale μs-to-ms conformational dynamics of
P2 assessed by 19F CPMG relaxation dispersion measurements for isoprenaline (red) (studied at 19F frequencies of 564MHz and 658MHz) and xamoterol
bound receptor (orange) (19F 564MHz). Best ﬁt curves to the dispersion data are shown together with values for kex and pP3 (pI2) obtained from the ﬁts.
The apo form of β1AR does not show any relaxation dispersion (green).
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conﬁrmed the presence of a second, alternative Nb6B9-coupled
receptor form.
Saturation transfer was used to assess a possible slow sub-
second exchange between the signals P5 and P6. A saturation
transfer time course with the saturation ﬁeld centred on P6 of
TM7 TETC344 (384 Hz upﬁeld from P5) in the presence of a two-
fold excess in Nb6B9 showed that P5 is in slow exchange with P6,
with kex= 8.1 ± 1.6 s−1 (Supplementary Fig. 10a). A second pre-
saturation experiment was conducted with the irradiation
position further upﬁeld from P6, at a sufﬁcient distance (684
Hz upﬁeld from P5) not to saturate P2 while still irradiating the
broad foot of the P6 signal (Supplementary Fig. 10b). This
resulted in a reduced but still noticeable response on P5 that is in
agreement with the broad nature of P6 and conﬁrmed the slow
exchange process to be taking place between P5 and P6, with
kex= 8.0 ± 1.5 s−1 showing a similar exchange rate (Supplemen-
tary Fig. 10).
Solvent-accessibility during ternary complex formation was
assessed with a soluble Gd3+ reagent (Supplementary Note 2).
Discussion
We investigated the cytoplasmic region of β1AR using 19F NMR
via TET ﬂuoro-tagging of the native C3447.54 in TM7 and of a
separately introduced A282C6.27 in TM6. These reporters were
used to study β1AR in the apo form and with a range of agonists
of varying efﬁcacy (in order of increasing efﬁcacy: atenolol, car-
vedilol, alprenolol, cyanopindolol, bucindolol, xamoterol, iso-
prenaline and the natural ligand adrenaline) as well as using a Gαs
protein mimetic nanobody Nb6B9 to form ternary receptor
complexes (Supplementary Table 1).
Our 19F NMR experiments show that the ligand-free β1AR is
mostly in an inactive state (I1), as indicated by a single, well-
deﬁned signal, P1, for TM6 (Fig. 2a) and P2 for TM7 (Fig. 2b).
This supports previous studies that focused on the transmem-
brane region of β1AR near the ligand binding pocket and showed
this region of the apo receptor to be much less dynamic than
when bound to full agonist16,17. In view of the inherent low basal
activity of the β1AR, the apo form is likely to be representative of
an inactive state, (I1).
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Fig. 3 19F saturation transfer experiments of TETC344 on TM7. The experiments identify a low populated signal P3 that is in slow exchange with P2. The
offset dependence of saturation for (a) the apo receptor (green), and (b) β1AR bound to isoprenaline (red) is probed in increments of 100 Hz. c Peak
intensity ratios from pairwise experiments with saturation at symmetrical offsets reveal a maximal response at −300 Hz relative to the corresponding
P2 signal (grey box). The response to saturation increases from the apo form to isoprenaline bound receptor. d Saturation time course for apo receptor
(green) and β1AR bound to isoprenaline (red) with the irradiation ﬁeld (ﬁeld strength 25 Hz) in the on-resonance experiment (circles) applied at the
position of P3, i.e. −300 Hz from P2. For the off-resonance reference experiment (crosses) saturation was applied at+300 Hz from P2. Best ﬁts for the
signal decays are shown by lines with values for kex and pP3 extracted from simultaneous ﬁts indicated for isoprenaline bound receptor as well as the
apo form.
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Probing the receptor with a range of agonists varying in efﬁ-
cacy revealed that the P1 signal for A282CTET, 6.27 showed only a
relatively small response to ligand binding (Supplementary
Note 3, Fig. 2a, Supplementary Figs. 6a, 12, 13).
In contrast, while the TM7 signal P2 of TETC3447.54 indicated
the apo receptor residing in an inactive form (I1), the signal P2
gradually moved further upﬁeld with increasing efﬁcacy of the
bound agonist (Fig. 2b, c, Supplementary Fig. 6b). At the same
time P2 also displayed increasing line-broadening (Fig. 2d). 19F
CPMG relaxation dispersion experiments conducted at two
ﬁelds for the receptor bound to isoprenaline revealed the presence
of a fast exchange process with the receptor interconverting
between two conformations, (I1) and (I2), with a rate kex= 2,878 ±
317 s−1 (Fig. 2e). For xamoterol the exchange rate was reduced to
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kex= 1,913 ± 299 s−1, while for the apo form of the receptor no
additional exchange contribution to the linewidth was detected in
the dispersion curve (Fig. 2e), in agreement with ligand-free β1AR
mostly populating an inactive state (I1). However, for xamoterol
and isoprenaline-bound receptor the second conformation (I2)
was increasingly populated. The low population of this second
state (I2) when in the apo form (pI2 = 0.02), with a slight increase
when bound to xamoterol (pI2= 0.11) and isoprenaline (pI2=
0.29), indicates that (I2) is likely a further inactive form of β1AR
(Fig. 2e). The timescale of the exchange process I1⇌ I2 is too
rapid to relate to substantial conformational rearrangements of
the TM7 environment as e.g. observed crystallographically in the
transition from the inactive state (PDB code 2YCY) to the fully
active state adopted in the ternary complex structure (PDB code
6H7J) (Fig. 1). Therefore, this process is most likely related to a
smaller change in the side chain conformation, potentially a
reorientation of the aromatic side chain of Y3437.53, one of the
conserved residues consistently observed to be involved in
receptor activation and IBP coupling (Fig. 5)11. An increase in the
population of (I2) with strong agonists such as isoprenaline
suggests that this conformational change might be linked to the
early stages of receptor activation, with (I2) possibly being an on-
pathway intermediate to a further downstream activated state.
Agonists would therefore shift the I1⇌ I2 equilibrium towards
(I2), facilitating subsequent activation.
In addition to the I1⇌ I2 equilibrium, the existence of a further
state (A) in slow exchange with the inactive (I1, I2) states of the
receptor (signal P2) was found indirectly through saturation
transfer experiments, which revealed the presence of a strongly
broadened peak at position P3, not directly detectable by 19F
NMR (Fig. 3). While only investigated for the apo and the iso-
prenaline bound receptor it became clear that the population of
this state increased with ligand efﬁcacy from pP3= 0.15 in the apo
form to pP3= 0.20 when isoprenaline bound. Substantial broad-
ening of this relatively low populated state prevented its direct
observation by 1D 19F NMR and suggested the occurrence of
substantial amounts of μs-to-ms conformational dynamics in the
vicinity of the NPxxY7.53 motif once the receptor was bound to
full agonists. We assume that the signal P3 corresponds to a pre-
active receptor state (A) that is competent to bind nanobody,
subsequently upon IBP coupling leading to the fully active state as
seen in the structures of the ternary complex of the receptor
(Fig. 5)37. The slow rate of exchange (ISO: kex = 6.9 ± 1.8 s−1,
APO: kex = 3.6 ± 1.6 s−1) between the states (I1, I2) and (A) is
indicative of major structural rearrangements taking place in this
region of the receptor. The exchange process (I1, I2)⇌ (A) hap-
pens on a similarly slow sub-second timescale as observed in
β2AR for the move of TM6 away from the helix bundle when
exchanging between inactive and active-like states, suggesting that
cytoplasmic TM6 and TM7 rearrangements might be related and
due to steric reasons occur in parallel14. Based on the reorienta-
tion of aromatic side chains in the immediate environment of
C3447.54 we calculated an increase in shielding of 0.16 ppm due to
changes in ring current shifts when moving from the inactive
structure of β1AR (approximated by the cyanopindolol bound
structure) (PDB code 2YCY) to the ternary complex with Nb80
(as an approximation of the pre-active receptor state) (PDB code
6H7J), suggesting a move of TETC3447.54 into a more hydro-
phobic environment upon reaching the pre-active state (Supple-
mentary Fig. 14, Supplementary Table 3). This is in reasonable
agreement with our experimental observation of P3 at a position
0.5 ppm upﬁeld from the apo receptor signal P2 (Fig. 3), and
suggests that the slow exchange process relates to the rotation and
inward movement of the intracellular part of TM7 that allows
Y7.53 following a change in the side chain rotamer conformation
to slot behind the displaced TM6 (Fig. 1). As expected, the
population of the (A) state increases with ligand efﬁcacy, reaching
20% for isoprenaline. This is in a similar range to the 25%
population found for the pre-active state using 13C methionine
NMR, as assessed by the reporters M2235.54 and M2966.4117. At
the same time the exchange rate seems to increase with ligand
efﬁcacy as well (kexISO > kexAPO) (Supplementary Fig. 2e).
Our observation of multiple inactive receptor states (I1, I2) for
β1AR agrees with several NMR studies and MD simulations on
β2AR15,19,38–40. The latter have suggested various intermediates
between active and inactive states during deactivation simulations
of β2AR, which in some cases showed a TM7 conformation dif-
ferent from the inactive or active state41. Different metastable
states for β2AR were found, with TM6 adopting active-like out-
ward as well as inward inactive-like conformations with TM7 not
having reached its active-state like conformation.
MD simulations into the formation of a continuous internal
water network during GPCR class A activation found such a
network to be interrupted in the inactive state by the presence of
two water-free layers of hydrophobic amino acid residues residing
above the NPxxY7.53 motif and below the conserved Y7.53 that
opened upon agonist activation to form a continuous water
channel connecting the orthosteric binding site to the G protein
interaction region42. Y7.53 was found to transition between three
rotamer conformations, representative of inactive (closed water
channel), meta state (water channel closed at cytoplasm) and
active state (open water channel). In the meta state, Y7.53
remained in a hydrophobic layer that breaks upon reaching the
fully active state as a continuous water channel is formed42. In
agreement with a potential meta state and the postulated model of
water accessibility, the environment of TETC3447.54 adjacent to
Y7.53 in our postulated pre-active (A) state is more hydrophobic
than in the (I1,2) states as suggested by the upﬁeld shift of P3
compared to P2 (Fig. 3, Supplementary Fig. 14)43. This agrees
with the suggestion that in the (A) state the hydrophobic layer
next to Y7.53 is still intact (Fig. 5). Accordingly, Y7.53 in the (A)
state might have already partly rotated into an alternative con-
formation while not yet reaching the fully active state. In agree-
ment with our experimental data this process is bound to be slow
Fig. 4 Ternary complex formation of β1AR coupled to nanobody Nb6B9. The experiments were conducted with the receptor in its apo form or in the
presence of a range of agonists. All spectra were obtained at 308 K, 564MHz (19F) with receptor concentrations of 20 − 30 μM, saturating concentrations
(1 mM) of agonists and a two-fold molar excess of Nb6B9 over β1AR. 19F NMR spectra of A282CTET (a) and TETC344 (b) are shown for ternary complexes
of β1AR in the apo form (light green), bound to carvedilol (brown), cyanopindolol (dark green), xamoterol (orange) and isoprenaline (red) (CVD carvedilol,
CYA cyanopindolol, XAM xamoterol, ISO isoprenaline). The spectra are shown from top to bottom in increasing efﬁcacy of the ligand bound. For reference
the position of the uncoupled apo form is shown by a green dotted line (P1, P2) and the position of the ternary nanobody coupled complex with isoprenaline
as a red dotted line (P4, P5). In (a) the grey dotted line (Δ) indicates the appearance of TET due to slow cleavage of the S-S bond at 308 K. The relative
integrals of the ternary complexes P4 (c) and P5 (d) linearly correlate with the ligand efﬁcacy. With increasing efﬁcacy the amounts of P1 and P2 are
decreasing. In (c) and (d) a black dashed line indicates the linear ﬁt to the measured data points, while a grey dashed line shows the corresponding linear ﬁt
that goes through the origin (based on the assumption that no ternary complex should be formed if the ligand efﬁcacy is 0%).
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as it involves the rotation and inward shift of TM7 and depends
on the outward movement of TM6 having already occurred.
Therefore, we suggest that the pre-active (A) state is competent to
bind nanobody but has not transitioned into the fully opened
conformation yet, retaining Y7.53 (and accordingly TETC3447.54)
in a hydrophobic environment.
Nanobodies such as Nb6B9 have been used to stabilise the
active state of receptors44,45. In the β2AR ternary complex they
maintain the receptor in a conformation very similar to the one in
the heterotrimeric Gs protein-bound complex46,47. Due to the
smaller size of the ternary nanobody complexes and their better
stability in detergents, we used Nb6B9 for our 19F NMR studies of
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Fig. 5 Schematic overview of β1AR ligand activation and ternary complex formation. Cartoon cross sections spanned by TM6, TM7 and H8 with the
TM7 TETC3447.54 probes shown as yellow spheres, adjacent to Y3437.53 of the NPxxY motif. The receptor exists in an equilibrium of inactive states (I1,2)
and a pre-active state (A), with the latter populated in growing amounts with increasing efﬁcacy of the bound ligand. Nanobody Nb6B9 addition leads to
the formation of a fully active ternary complex (AG+) in amounts proportional to the ligand efﬁcacy. Nanobody binding also occurs with the inactive form of
the receptor, resulting in the formation of (AG−). The latter can be considered as a pre-coupled inactive form, with inactive and active ternary complexes in
slow exchange with each other. The binding interface in the (AG−) complex is shown faded, emphasising that Nb6B9 has not yet fully engaged the epitope
characteristic of the active receptor state. The (I1)⇌ (I2) interchange takes place on a μs-to-ms timescale, while the (I2)⇌ (A) interchange as well as the
(AG−) ⇌ (AG+) exchange occurs on a slower sub-second timescale. Exchange rates, where measured, are indicated below the equilibrium arrows. In the
ternary state (AG+) the cytoplasmic region of TM6 is rigid while TM7 remains dynamic on the μs-to-ms timescale, implied by TM7 showing partly blurred.
In (AG+) the conformation of TM7 in the vicinity of the NPxxY motif reveals agonist-dependent conformational differences, emphasised by TM7 showing
in different colours in the enlarged region marked with (*). The grey slider below each receptor cartoon approximates the relative hydrophobic/hydrophilic
extent of the TM7 19F NMR probe surrounding in that particular state. Lipid bilayer hydrophobic regions are shown in light grey. Dark grey areas indicate
transmembrane regions of the receptor with residues rich in hydrophobic side chains. These form hydrophobic gates above and below the NPxxY region
(e.g. in I1 and I2) that shield the receptor interior against bulk water access. Blue dots on a grey background (e.g. in I1, I2 and AG−) indicate ordered internal
water molecules, separated from the bulk water through the hydrophobic gates (dark grey). Conformational changes upon activation disrupt the two
hydrophobic side chain layers, resulting in the gradual opening of a continuous internal water pathway with cytoplasmic inﬂux of bulk water, as indicated by
the speckled grey/blue area between TM6 and TM7 in (A) and (AG+).
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β1AR. Several crystal structures of β1AR-nanobody complexes are
now available (Supplementary Fig. 15)37.
Addition of a two-fold excess of Nb6B9 to samples of β1AR
either bound to one of the diverse partial or full agonists used or in
the receptor apo form led to the formation of an active state ternary
complex (AG+) for each of the samples investigated, as evidenced
by the appearance of a new 19F NMR signal P4 for the TM6 probe
(Fig. 4a) and a signal P5 for TM7 (Fig. 4b). The P4 and P5 peaks
were shifted substantially downﬁeld from the signals of the
uncoupled receptors. We were unable to rationalise the observed
large 19F chemical shift changes between the ternary complexes and
the ligand bound receptors through ring current shift calculations
that relied on the known structural coordinates (Supplementary
Figs. 13, 14). It is likely, therefore, that the observed 19F shift
changes result mainly from variations in the solvent exposure of
A282CTET and TETC344 when adopting the ternary state. Although
chemical shift changes for 19F are difﬁcult to predict, the effects of
variations in polarity were investigated by Ye et al. where a
downﬁeld shift was found to be indicative of an increase in solvent
polarity or augmented solvent exposure43. Full activation into
the ternary state results in the outward movement of TM6 and
rotation of TM7 with the inward movement of the NPxxY7.53 motif
(Fig. 1, Supplementary Fig. 16), that allows Y7.53 to adopt the
conformation that is unique to the active state by forming polar
contacts with Y5.58 on TM5 and water-mediated polar contacts to
other residues, slotting behind TM6 (Fig. 1)11. The large downﬁeld
shifts observed upon formation of the ternary states suggest
changes in the polarity of the local environment with A282CTET
and TETC344 experiencing greater solvent exposure in the fully
active state of the ternary complex. This can be understood as
A282C6.27 moves outwards away from the TM core, while for
C3447.54, the hydrophobic layer adjacent to the cytoplasm is now
opened forming a continuous water channel between the ligand-
binding pocket and cytoplasm (Fig. 5). Further discussion on the
solvent exposure of the 19F probe can be found in the supple-
mentary information (Supplementary Note 4, Supplementary
Figs. 11, 17, 18).
For each agonist-bound receptor sample, the relative amount
of ternary nanobody complex (AG+) formed was determined by
integration of the corresponding NMR signal. For both
A282CTET (signal P4) (Fig. 4c) and TETC344 (signal P5) (Fig. 4d),
the amounts of active ternary complex (AG+) in solution corre-
lated very well with the efﬁcacy of the bound agonist in the
complex. Although ligand efﬁcacy values are typically derived
from cell-based assays, our experiments illustrate that agonist Gs
directed signalling efﬁcacy and the phenomenon of partial
agonism closely relate to the total molecular amount of ternary
receptor complex formed, as assessed here in vitro by two inde-
pendent probes located at the cytoplasmic ends of TM6 and TM7.
For TM6, all active ternary complexes (AG+) showed P4 at the
same chemical shift position indicating a strong similarity in the
conformational environment of A282CTET across the different
complexes (Fig. 4a), regardless to which ligand the receptor was
bound. The signals were sharp with narrower linewidths than for
the ligand-only bound receptor signals P2 (Fig. 4a, Supplemen-
tary Table 2), indicating the absence of any dynamics near
A282CTET that would broaden the NMR signal. This is in
agreement with previous observations with full-agonist iso-
prenaline bound β2AR, which resulted in a sharper signal upon
coupling to Nb80, as was assessed by a BTFMA probe attached to
C2656.27 19. Interestingly, our previous 13C NMR study on β1AR
indicated that the region of TM6 below the binding pocket was
still mobile, with the dynamics showing a dependency on the type
of ligand bound, as assessed by M2966.41 17 This suggests that
even in the ternary state increased mobility persists in the regions
of the allosteric network that are closer to the orthosteric binding
pocket. In contrast, based on our 19F NMR data, TM6 seems
likely to be more ordered near the cytoplasm, once the con-
formation that couples with the nanobody has been engaged.
Accordingly, a single conformation for TM6 near A282CTET is
adopted (Fig. 4a). This agrees with the cytoplasmic side of TM6 in
its active signalling conformation guiding the positioning of the
IBP, while the type of binding partner dictates the extent of
displacement of the cytoplasmic end of TM6 relative to the
receptor core. Therefore, a more rigid arrangement at the cyto-
plasm is suggested to increase the efﬁciency of the signalling
transfer onto the coupling partner, while the residual dynamics
below the orthosteric binding pocket in the receptor core main-
tain the allosteric signal transmission initiated by the orthosteric
ligand bound.
In contrast, the appearance of the signal P5 from the cyto-
plasmic region of TM7 in the same complexes varied over a wide
range of 0.3 ppm with the position of P5 determined by the
orthosteric ligand bound (Fig. 4b, Supplementary Fig. 9d). This
indicates that TETC3447.54 reveals succinct ligand-dependent
conformational differences in the adjacent NPxxY7.53 motif and/
or helix 8 amongst the different agonist-bound ternary receptor
complexes. Furthermore, all the ternary complex P5 signals of
TM7 TETC3447.54 were strongly broadened, supporting the pre-
sence of substantial μs-to-ms dynamics as this receptor region
continues to sample multiple conformations (Fig. 4b, Supple-
mentary Table 2). We tested whether the signal positions of P5
correlate with the efﬁcacy of the ligands bound in the respective
ternary complexes. A correlation would suggest that partial
agonism is not only controlled via the amount of signalling
complex formed but also via the adopted conformation at the
cytoplasm of TM7. The weak correlation (R2= 0.51) between
ligand Gs efﬁcacy and chemical shift position of P5, however,
indicated that this is not the case (Supplementary Fig. 9c).
Therefore, the observed conformational variability of the NPxxY
motif on TM7 seems unrelated to Gs protein signalling (Sup-
plementary Note 5, Supplementary Figs. 15, 19).
The difference in the conformational response of TM6 and
TM7 to Nb6B9 binding is remarkable and suggests a potential
role for the TM7 NPxxY7.53 motif that extends beyond the sta-
bilisation of the fully active state. Possibly this might indicate a
tendency for this receptor region to engage alternative signalling
pathways, be related to biased signalling, be relevant for IBP
coupling speciﬁcity or reveal an additional layer of Gs indepen-
dent signalling control that is determined by the orthosteric
ligand. It is remarkable to note in this context that the carvedilol-
bound complex resulted in the most downﬁeld shifted peak and
the largest difference to the balanced full agonist isoprenaline
(Fig. 4b, Supplementary Fig. 9d). Previously, carvedilol has been
associated with β1AR biased signalling33,35,36. For the biased
agonist bucindolol the effect is less pronounced with a shift
similar to cyanopindolol. Accordingly, the biased agonist carve-
dilol might induce a conformation on TM7 of β1AR upon Gs
protein binding that facilitates binding of further IBPs such as e.g.
β-arrestin, leading to distinct cellular signalling outputs. Indeed,
such complexes of GPCRs, β-arrestin and a G protein have been
reported48.
19F NMR studies of the β2AR have previously reported a semi-
independent response of the TM6 and TM7 conformational
equilibria following binding of orthosteric ligands of differing
bias18,49. It was postulated that arrestin biased ligands pre-
ferentially activated TM7 over TM6, suggesting an involvement of
TM7 in biased signalling. Our 19F NMR data for the ligand-bound
β1AR do not show such a response, possibly hindered through the
inaccessibility of the P3 signal. In contrast, we observe a ligand
dependent variability of the signal position for TM7 in ternary
complexes of β1AR (Fig. 4b) that seems largely decoupled from the
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response of TM6. As for the β2AR this might indicate therefore
that TM7 in β1AR plays a role in signal bias.
In order to assess the maximal amount of ternary complex that
can be formed with nanobody we supplemented β1AR bound to
carvedilol, xamoterol or isoprenaline, with a 2-fold, a 5-fold and a
10-fold excess of Nb6B9. Similar looking ligand-efﬁcacy depen-
dent saturation curves were obtained for TM6 and TM7 (Sup-
plementary Fig. 9a). From our previous 13C NMR study, it was
known that at such an excess of nanobody there is no uncom-
plexed β1AR left in solution17. Hence, the P2 signal (I1, I2 state) of
the uncoupled receptor should have vanished. Upon closer
inspection of the spectrum near the position of the P2 signal of
TETC344 we realised the gradual appearance of a new, broad peak
P6 located in a very similar position to P2 that grew with the
amount of Nb6B9 added (Supplementary Fig. 9b). In contrast the
sharper, original P2 signal of the free receptor was gradually
disappearing upon nanobody addition. Deconvolution of the P2/
P6 region of the spectra using two Lorentzian signals conﬁrmed
the presence of the sharper P2 signal and the broader P6 signal
(Supplementary Table 2), with the intensity of the latter
increasing and P2 decreasing as more nanobody was added
(Supplementary Fig. 8g, h). Due to its similarly broad lineshape to
the active ternary signal, P5, we conclude that in P6 the receptor
is also nanobody-bound and hence also in a ternary complex.
However, its signal position, similar to P2, suggests an inactive
receptor complex, possibly indicating pre-coupling of the recep-
tor to nanobody. Very likely this signal is related to the minor
active ternary form (AG−) observed in our methionine 13C NMR
study17. This form should also be present for TM6, however, due
to the lack of dispersion in this region and the similarity in
linewidths between ternary (P4 signal) and ligand-only bound
receptor (P1 signal), it is not as clearly manifested except for the
xamoterol complex where it can be observed through an increase
of the signal linewidth at the position of P1 compared to the
ligand-only bound form (Supplementary Table 2). Using
saturation transfer at two offsets we established a slow sub-second
timescale exchange between P5 (AG+) and P6 (AG−) (Supple-
mentary Fig. 10).
The results of our 19F NMR study are summarised in a model
shown in Fig. 5. Ligand binding acts as a functional modulator by
shifting the populations between interconverting inactive (I1, I2)
and pre-active (A) states, with the latter increasingly populated
with higher efﬁcacy ligands. Conformational exchange between
inactive and pre-active states takes place on a sub-second time-
scale, while (I1, I2) exchange occurs on the μs-to-ms timescale.
Pre-active but also inactive receptor states can couple to Nb6B9
forming two type of ternary complexes. The latter interconvert on
a slow sub-second timescale. The total amount of active complex
(AG+) formed ultimately reﬂects the level of efﬁcacy towards Gs
signalling for a given ligand. While the TM6 environment in the
active ternary state is rigid, the TM7 environment remains
dynamic. The active complexes with different ligands display
conformational variability in the vicinity of the NPxxY7.53 motif
on TM7 (Fig. 5 inset), with possible functional implications.
Based on concepts from MD simulations42, we indicate two layers
consisting predominantly of hydrophobic side chains that act as
hydrophobic gates (Fig. 5, dark grey areas) surrounding the
NPxxY motif. These gates are disrupted in the AG+ state allowing
the formation of a continuous water pathway from the ligand
pocket to the cytoplasm. The hydrophobicity of the environment
surrounding the TM7 probe varies between the different states, as
indicated by the position of the yellow sphere on the slider below
each structure cartoon (Fig. 5). AG− might represent a pre-
coupled form of the receptor that can convert into the active state
AG+, its existence might be particular to the use of nanobody as a
GS mimetic or be related to its binding afﬁnity, in view of the
excess of nanobody over receptor used. In Fig. 5 the position of
TM6 and TM7 in AG− is shown less open than in AG+, to
emphasise that the receptor has not adopted the fully active
state yet.
In conclusion, we investigated the response of the under-
explored cytoplasmic region of turkey β1AR to ligand activation
and nanobody binding using 19F NMR in combination with TET
labelling of two cysteine probes located on TM6 A282C6.27 and
TM7 C3447.54. We show that allosteric signal transmission
initiated by agonist binding leads to the population of different
inactive and pre-active receptor states that are in equilibrium with
each other, gradually shifting the receptor towards a more active
state as higher efﬁcacy ligands are used. Coupling of a Gs protein
mimetic nanobody to receptors bound to agonists of varying
efﬁcacy results in the formation of an active ternary receptor
complex. The total amount of the latter relates to the efﬁcacy of
the ligand bound, indicating that signalling output is proportional
to the amount of this species formed, providing a molecular link
to the concept of partial agonism. The responses of TM6 and
TM7 upon nanobody binding, however, are very different. The
cytoplasmic side of TM6 is well ordered, determined by the IBP
coupling partner, shows no evidence of μs-to-ms dynamics and
reveals the same conformation for different agonists bound. In
contrast, TM7 displays distinct conformational variability in the
vicinity of the NPxxY motif that depends on the agonist bound
and in addition is dynamic on a μs-to-ms timescale. These
agonist-dependent conformational differences in the NPxxY
motif in the ternary complexes suggest a further mechanistic role
of this receptor region and indicate that the response of TM6 and
TM7 are partly decoupled from each other even in the ternary
states. The conformational differences at the cytoplasm of TM7
are particularly pronounced between the ternary complexes with
unbiased agonists and the one with the biased agonist carvedilol,
suggesting a functional role.
Methods
β1AR construct generation. The turkey β1AR-m-CysΔ2 construct was modiﬁed
from the previously published β1AR-Met2-Δ5 construct by introducing two
cysteine mutations at position C85V2.48 and C163L4.47 17. Primer sequences are
given in Supplementary Table 4. Differences between the β1AR-m-CysΔ2 and the
wildtype β1AR are truncations at the N-terminus, C-terminus and IL3, three
thermostabilising mutations (R68S1.59, E130W3.41, F327A7.37), ﬁve methionine
substitution mutations (M44L1.35, M48L1.57, M179LEL2, M281AIL3, M338A7.48)
and four cysteine substitution mutations (C85V2.48, C163L4.47, C116L3.27 for yield
improvement and C358A to remove a palmitoylation site). The ﬁve methionine
mutations are not required for this work but were maintained for comparison
purposes with our earlier work17. The amino acid sequence for β1AR-m-CysΔ2 is
MGAELLSQQWEAGLSLLLALVVLLIVAGNVLVIAAIGSTQRLQTLTNLFITS
LAVADLVMGLLVVPFGATLVVRGTWLWGSFLCELWTSLDVLCVTASIWTLC
VIAIDRYLAITSPFRYQSLMTRARAKVIILTVWAISALVSFLPIMLHWWRDEDP
QALKCYQDPGCCDFVTNRAYAIASSIISFYIPLLIMIFVYLRVYREAKEQIRKIDR
ASKRKTSRVAAMREHKALKTLGIIMGVFTLCWLPFFLVNIVNVFNRDLVPD
WLFVAFNWLGYANSAANPIIYCRSPDFRKAFKRLLAFPRKADRRLHHHHHH
HH.
The β1AR-m-TM6-CysΔ2 construct was generated from the β1AR-m-CysΔ2
construct through cysteine substitution C344S7.54 and introduction of the non-
native cysteine C282 through mutation A282C6.27. The amino acid sequence for
β1AR-m-TM6-CysΔ2 is
MGAELLSQQWEAGLSLLLALVVLLIVAGNVLVIAAIGSTQRLQTLTNLFITS
LAVADLVMGLLVVPFGATLVVRGTWLWGSFLCELWTSLDVLCVTASIWTLC
VIAIDRYLAITSPFRYQSLMTRARAKVIILTVWAISALVSFLPIMLHWWRDEDP
QALKCYQDPGCCDFVTNRAYAIASSIISFYIPLLIMIFVYLRVYREAKEQIRKIDR
ASKRKTSRVACMREHKALKTLGIIMGVFTLCWLPFFLVNIVNVFNRDLVPDW
LFVAFNWLGYANSAANPIIYSRSPDFRKAFKRLLAFPRKADRRLHHHHHHHH.
β1AR expression, puriﬁcation and 19F labelling. All receptor expressions were
performed using the FlashBac baculovirus insect cell expression system. Trans-
fection reactions for baculovirus generation were prepared by mixing 0.2 µg of
pBacPak8 plasmid containing the β1AR expression constructs with 4 µL Cellfectin
II (Thermo Fisher Scientiﬁc), 2 µL FlashBac DNA (Oxford Expression Technolo-
gies) and 100 µL of Insect Xpress medium (Lonza). The transfection reaction was
incubated for 30 min at room temperature and then applied directly onto adherent
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Sf9 insect cells seeded at a density of 0.5 × 106 cells per mL in a culture volume of
1 mL. The transfection reaction was incubated at 27 °C for 5 days shaking at 90 rpm.
After incubation, the cells were visually inspected for signs of viral infection. The
resulting cell supernatant containing the recombinant baculovirus was harvested
(P0 virus generation) and was used for further rounds of viral ampliﬁcations.
For expression, Sf9 insect cell cultures at a density of 1 to 1.5 × 106 cells per mL
were infected with 4 mL virus stock per 1 L Sf9 cell culture. The expression was
carried out for 48 to 72 h at 27 °C shaking at 160 rpm and the cells were
subsequently harvested by centrifugation (4000g, 10 min, 4 °C). Resulting cell
pellets were either used directly for β1AR puriﬁcation or stored at −20 °C.
Extraction of the β1AR from insect cell membranes was performed by
resuspension of the cell pellet with solubilisation buffer (20 mM Tris pH 8, 350 mM
NaCl, 1% LMNG, 3 mM imidazole, Complete protease inhibitor (Roche)). The
solubilisation was incubated for 1 h at 4 °C with stirring and the resulting
suspension was cleared by centrifugation (175,000 g, 45 min, 4 °C). The cleared
supernatant was applied onto a HisTrap FF 5 mL Nickel afﬁnity column on an
AKTA Pure (GE Healthcare) pre-washed with equilibration buffer (20 mM Tris pH
8, 350 mM NaCl, 0.02% LMNG, 3 mM imidazole). After protein binding, the
column was washed in steps with the same buffer containing 3 mM, 50 mM and
250 mM imidazole, the latter eluting β1AR.
The labelling of the β1AR with the 19F probe 2,2,2-Triﬂuoroethanethiol (TET)
was performed according to Supplementary Fig. 232. In brief, the nickel afﬁnity
chromatography elution fractions were combined and concentrated (Amicon
Ultra-15 spin concentrator with 50 kDa molecular weight cutoff) to 10 µM protein
concentration. To activate cysteine side chains for 19F labelling, 4-4′-
Dithiopyridine (commercially available as Aldrithiol-4TM, Sigma-Aldrich) was
added in a tenfold molar excess (100 µM) together with oxidised glutathione in a
ﬁvefold molar excess (50 µM). The solution was stirred at 4 °C for 20 min. After
incubation, Aldrithiol-4TM and oxidised glutathione were removed by 1000× dilute
concentration into 20 mM Tris pH 8, 350 mM NaCl and 0.02% LMNG. Following
buffer exchange, 100 µM TET together with 50 µM oxidised glutathione were
added and the solution was incubated for 30 min at 4 °C with stirring. The TET and
oxidised glutathione were removed by 1000× dilute concentration into 20 mM Tris
pH 8, 350 mM NaCl and 0.02% LMNG. The labelled β1AR was further puriﬁed by
alprenolol ligand afﬁnity chromatography and the functional receptor eluted with
either 1 mM atenolol or 0.1 mM alprenolol (Supplementary Figs. 21, 22).
Although not monitored routinely as untagged receptor is invisible to our
investigations the efﬁciency of the 19F labelling reaction was estimated from small-
scale receptor preparations to be on the order of 80–95%. The estimate is based on
the intensity comparison of the 19F NMR signal of free TET, released from the
receptor following reduction of the S–S bond with DTT, relative to an external TET
standard and the intensity of the SEC A280 signal of β1AR prior to the labelling
reaction.
Similar labelling reactions were also attempted with the reagents 3-bromo-1,1,1-
triﬂuoroacetone (BTFA) or 2-bromo-N-(4-(triﬂuoromethyl)phenyl)acetamide
(BTFMA), respectively (Supplementary Methods, Supplementary Fig. 3)
Expression and puriﬁcation of Nb6B9. The expression and puriﬁcation of Nb6B9
followed established protocols17. In brief, the nanobody Nb6B9 was expressed in
BL21-RIL E.coli cells and the cell pellets were lysed before clearing the lysate by
centrifugation (75,600 g, 4 °C, 30 min). The cleared lysate was applied onto a
HisTrap FF 5 mL Nickel afﬁnity column on an AKTA Pure (GE Healthcare) pre-
washed with equilibration buffer (20 mM Tris pH 8, 150 mM NaCl) and washed
with the same buffer containing 15 mM imidazole before eluting the bound protein
with 250 mM imidazole. The elution fractions were further used for cation
exchange chromatography using a RESOURCE S column (GE Healthcare) pre-
washed with equilibration buffer (50 mM Sodium Acetate pH 4.8, 75 mM NaCl).
The nanobody was eluted from the RESOURCE S column with a linear NaCl
gradient ranging from 75 mM to 1M NaCl. The pure Nb6B9 was ﬁnally buffer
exchanged into 10 mM Tris pH 8, 150 mM NaCl and concentrated to approxi-
mately 1 mM protein concentration.
NMR experiments. NMR samples containing 5% D2O were prepared with ligand
added to a ﬁnal agonist concentration of 1 mM (atenolol, carvedilol, alprenolol,
cyanopindolol, bucindolol, xamoterol, isoprenaline, adrenaline) to the apo form
of β1AR receptor (20–50 μM) solubilized in 1% LMNG. The population of the
ligand-bound receptor exceeded 99.9%. Nanobody was added in two-fold molar
excess for ternary complex formation, unless speciﬁed otherwise. NMR spectra
were recorded at 308 K on a 600MHz (1H) and 700MHz (1H) Bruker Avance III
spectrometer equipped with a 5 mm QCI HFCN/z cryoprobe (19F 564MHz) and a
5 mm TCI HCN/z cryoprobe (19F 658MHz), tuneable to 19F (The Francis Crick
Institute, London). 1D 19F NMR data were obtained with a pulse acquire experi-
ment recording 2560 complex points (50 ms), using a repetition time of 1 s and
5000 to 30,000 scans, resulting in a total experiment time varying between 2 and
12 h, ensuring that the signal-to-noise ratio was at least 30. To investigate the
presence of μs-to-ms timescale dynamics leading to line broadening of P2, 19F
CPMG relaxation dispersion measurements were recorded as a series of 1D
experiments using a constant time implementation with a total transverse
decay period of 10 ms, which allowed νCPMG to be increased from 100 to 5000 Hz
(νCPMG= 1/(4*τCPMG). Dispersion curves with 10 relaxation points were measured
at 564MHz (19F) and 658MHz (19F) (The Francis Crick Institute), which took
2 days per series. The consistencies of the samples were monitored over the course
of the relaxation dispersion series by 1D 1H and 19F NMR, so that signal losses due
to hydrolysis of the TET-tag or receptor degradation could be corrected for.
To investigate slow exchange on the chemical shift timescale between P2 and
P3, and between P5 and P6, a series of 1D saturation transfer experiments was
recorded at 564MHz (19F) where the initial excitation pulse was preceded by a 2 s
recovery delay followed by a 1000 ms saturation period (saturation ﬁeld strength of
25 Hz). For each of the experiments the position of the saturation ﬁeld was
incremented by 100 Hz, covering a range between −1100 Hz and 1100 Hz relative
to the main signal of interest (P2 or P5). Comparing the pairwise intensities
in the symmetrically irradiated experiments (on-resonance vs off-resonance
(i.e. reference) experiment), the saturation offset with the strongest response was
determined (for P3, saturation at −300 Hz relative to P2; for P6, saturation at
−384 Hz relative to P5). Two time courses (8 points) were measured with the
saturation length varying from 25 ms to 1000 ms and the saturating ﬁeld positioned
at ±300 Hz (P3), or ±384 Hz (P6) relative to the main peak. For P6 a second time
course was measured with the saturation position changed to ± 684 Hz. Sample
consistency was checked by 1D 1H and 19F NMR.
Solvent accessibility changes for β1AR-m-CysΔ2 TETC344 were assessed for the
receptor in the presence of xamoterol (1 mM) and a two-fold excess in Nb6B9
through addition of increasing concentrations (0, 1, 3, 5 mM) of the Gd3+
paramagnetic relaxation agent gadopentetic dimeglumine (Magnevist). Signal
intensities and R2 values for P2 and P6 were analysed as a function of Gd3+
concentration. R2 values were obtained from a two-point relaxation measurement
by comparing the intensities in a CPMG experiment (νCPMG= 5000 Hz) with the
CPMG reference experiment.
All acquired FIDs were apodized with 20Hz line broadening prior to zeroﬁlling
to 64k points and FFT using Topspin 3.1. 19F chemical shifts were calibrated with an
internal standard of 2 μM triﬂuoroacetic acid (TFA) at −76.55 ppm relative to
CFCl3. All signals P1 to P6 were deconvoluted as Lorentzian lines to obtain the R2
values related to the linewidth at half-height (Supplementary Fig. 8, Supplementary
Table 2). R2,eff values from CPMG data were obtained from signal intensities
according to R2,eff= (1/T) × ln[I1(νCPMG) /I0], with T being the length of the constant
time period (10ms), I1 the signal intensity with the 180˚ pulse train and I0 the
reference intensity in the absence of the constant time period. The errors in R2,eff
were estimated from the noise in the spectra and from spectral variation. Fitting of
the CPMG relaxation dispersion data and extraction of ﬁtting parameters was done
using in-house written software based on the methodology described by Baldwin50.
The dispersion data was modelled as a two-state exchange process, with
simultaneous ﬁtting of the data recorded at two ﬁelds. Fitting was repeated for a
range of offset differences Δω between the exchanging states (I1) and (I2), ranking
the results by their summed squared residuals. Combining the values from the best
ﬁt with the chemical shift changes of the P2 peak for different ligands, the exchange
rate kex for I1⇌ I2 and the populations of the exchanging states pI1 and pI2 were
determined. Analysis of the slow-exchange saturation transfer experiments was done
based on the Bloch–McConnell formalism using in-house written software to obtain
kex and pP3 from simultaneously ﬁtting the on- and off-resonance time courses51,52.
MD simulations. The ternary structure model of β1AR bound to xamoterol in
complex with Nb6B9 (PDB ID 6H7N) was modiﬁed by coupling the cysteine side
chain Sγ positions of C344 and A282C to TET and prepared for MD simulations
with the Schrödinger 6 protein preparation wizard under the OPLS_2005 force
ﬁeld. The structure was embedded in a fully hydrated POPC bilayer coupled to
TIP3P water molecules, using the OPLS3 force ﬁeld for building the system and the
steepest descent algorithm for energy minimisation. MD simulation time was set to
1 ns at constant volume and temperature, followed by 1 ns at constant pressure and
temperature for initial system equilibration, while further extending the simulation
time to 12 ns at 300 K.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that relevant data supporting the ﬁndings of this study are available
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